Cholesterol biosynthesis inhibitors as potent novel anti-cancer agents: suppression of hormone-dependent breast cancer by the oxidosqualene cyclase inhibitor RO 48-8071

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Breast Cancer Research and Treatment

• Publication date

  2014-05-31

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/s10549-014-2996-5PMID 24878988PMCID PMC11121502
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Sex hormone receptors in breast cancer.

  2013cited by this paper
• 27-Hydroxycholesterol promotes cell-autonomous, ER-positive breast cancer growth.

  2013cited by this paper
• 27-Hydroxycholesterol Links Hypercholesterolemia and Breast Cancer Pathophysiology

  2013cited by this paper
• Fulvestrant-Induced Cell Death and Proteasomal Degradation of Estrogen Receptor α Protein in MCF-7 Cells Require the CSK c-Src Tyrosine Kinase

  2013cited by this paper
• Estrogen receptor alpha/beta ratio and estrogen receptor beta as predictors of endocrine therapy responsiveness–a randomized neoadjuvant trial comparison between anastrozole and tamoxifen for the treatment of postmenopausal breast cancer

  2013cited by this paper
• Cytotoxic effects of combination of oxidosqualene cyclase inhibitors with atorvastatin in human cancer cells.

  2012cited by this paper
• Estrogen receptor prevents p53-dependent apoptosis in breast cancer

  2012cited by this paper
• The turnover of estrogen receptor α by the selective estrogen receptor degrader (SERD) fulvestrant is a saturable process that is not required for antagonist efficacy.

  2011cited by this paper
• An inverse docking approach for identifying new potential anti-cancer targets.

  2011cited by this paper
• Apigenin Prevents Development of Medroxyprogesterone Acetate-Accelerated 7,12-Dimethylbenz(a)anthracene-Induced Mammary Tumors in Sprague–Dawley Rats

  2011cited by this paper
• The different roles of ER subtypes in cancer biology and therapy

  2011cited by this paper
• Minireview: Estrogen receptor-beta: mechanistic insights from recent studies.

  2010cited by this paper
• The role of estrogen receptor beta (ERbeta) in malignant diseases--a new potential target for antiproliferative drugs in prevention and treatment of cancer.

  2010cited by this paper
• Targeting mutant p53 protein and the tumor vasculature: an effective combination therapy for advanced breast tumors

  2010cited by this paper
• Epidermal growth factor receptor cross-talks with ligand-occupied estrogen receptor-alpha to modulate both lactotroph proliferation and prolactin gene expression.

  2009cited by this paper
• Estrogen receptor beta exerts growth-inhibitory effects on human mammary epithelial cells

  2009cited by this paper
• Biological determinants of endocrine resistance in breast cancer

  2009cited by this paper
• Effects of estradiol and progestogens on tumor-necrosis factor-alpha-induced changes of biochemical markers for breast cancer growth and metastasis

  2008cited by this paper
• Aromatase expression in women's cancers.

  2008cited by this paper
• Influence of Cellular ERα/ERβ Ratio on the ERα-Agonist Induced Proliferation of Human T47D Breast Cancer Cells

  2008cited by this paper
• A genome-wide study of the repressive effects of estrogen receptor beta on estrogen receptor alpha signaling in breast cancer cells

  2008cited by this paper
• Squalene synthase inhibitors : clinical pharmacology and cholesterol-lowering potential.

  2007cited by this paper
• Re-activation of the p53 pathway inhibits in vivo and in vitro growth of hormone-dependent human breast cancer cells.

  2007cited by this paper
• Estrogen receptor beta inhibits angiogenesis and growth of T47D breast cancer xenografts.

  2006cited by this paper
• Sex-steroid regulation of vascular endothelial growth factor in breast cancer.

  2006cited by this paper
• Estrogen Receptor β Inhibits Angiogenesis and Growth of T47D Breast Cancer Xenografts

  2006cited by this paper
• Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells

  2006cited by this paper
• Estrogen receptor positive breast cancer metastasis: altered hormonal sensitivity and tumor aggressiveness in lymphatic vessels and lymph nodes.

  2006cited by this paper
• Vascular endothelial growth factor induces proliferation of breast cancer cells and inhibits the anti-proliferative activity of anti-hormones.

  2006cited by this paper
• Steroid receptors and their role in the biology and control of breast cancer growth.

  2006cited by this paper
• Isoprenylated proteins

  2005cited by this paper
• Insight into steroid scaffold formation from the structure of human oxidosqualene cyclase

  2004cited by this paper
• Estrogen receptor β inhibits 17β-estradiol-stimulated proliferation of the breast cancer cell line T47D

  2004cited by this paper
• Estrogen Receptor β Inhibits Human Breast Cancer Cell Proliferation and Tumor Formation by Causing a G2 Cell Cycle Arrest

  2004cited by this paper
• Estrogen receptor beta inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cell cycle arrest.

  2004cited by this paper
• Estradiol abrogates apoptosis in breast cancer cells through inactivation of BAD: Ras-dependent nongenomic pathways requiring signaling through ERK and Akt.

  2004cited by this paper
• Estrogen receptor beta inhibits 17beta-estradiol-stimulated proliferation of the breast cancer cell line T47D.

  2004cited by this paper
• Estrogen receptor (ER)-beta reduces ERalpha-regulated gene transcription, supporting a "ying yang" relationship between ERalpha and ERbeta in mice.

  2003cited by this paper
• Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial.

  2003cited by this paper
• Synthesis and structure-activity studies of novel orally active non-terpenoic 2,3-oxidosqualene cyclase inhibitors.

  2003cited by this paper
• Estrogen Receptor (ER)-β Reduces ERα-Regulated Gene Transcription, Supporting a “Ying Yang” Relationship between ERα and ERβ in Mice

  2003cited by this paper
• The NEDD8 pathway is required for proteasome-mediated degradation of human estrogen receptor (ER)-alpha and essential for the antiproliferative activity of ICI 182,780 in ERalpha-positive breast cancer cells.

  2003cited by this paper
• Relationship between long durations and different regimens of hormone therapy and risk of breast cancer.

  2003cited by this paper
• Squalene Synthase Inhibitors

  2003cited by this paper
• Influence of Estrogen Plus Progestin on Breast Cancer and Mammography in Healthy Postmenopausal Women: The Women's Health Initiative Randomized Trial

  2003cited by this paper
• ICI 182,780 (Fulvestrant™) – the first oestrogen receptor down-regulator – current clinical data

  2001cited by this paper
• RESPONSE: re: effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin

  2000cited by this paper
• C-erbB-2 overexpression and survival in early onset breast cancer

  2000cited by this paper
• Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin.

  2000cited by this paper
• Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk.

  2000cited by this paper
• Proteasome-dependent degradation of the human estrogen receptor.

  1999cited by this paper
• Molecular mechanisms of steroid hormone action

  1998cited by this paper
• Endocrine aspects of the clinical management of breast cancer - current issues

  1998cited by this paper
• Hormone-dependent cancer

  1996cited by this paper
• The estrogen antagonist ICI 182,780 reduces cancellous bone volume in female rats.

  1993cited by this paper
• HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma.

  1992cited by this paper
• Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients: findings from National Surgical Adjuvant Breast and Bowel Project Protocol B-06.

  1988cited by this paper

• The Estrogen Receptor Beta Agonist Liquiritigenin Enhances Growth Inhibition of TNBC by the Cholesterol Biosynthesis Inhibitor RO 48-8071

  2025cites this paper
• Lycorine hydrochloride inhibits cholangiocarcinoma through cholesterol biosynthesis and PTPN11 nuclear translocation

  2025cites this paper
• Thermal proteome profiling and proteome analysis using high‐definition mass spectrometry demonstrate modulation of cholesterol biosynthesis by next‐generation galeterone analog VNPP433‐3β in castration‐resistant prostate cancer

  2025cites this paper
• Lipid-laden macrophages in atherosclerosis and cancer.

  2025cites this paper
• Impact of De Novo Cholesterol Biosynthesis on the Initiation and Progression of Breast Cancer

  2024cites this paper
• Synergistic Effects of PARP Inhibition and Cholesterol Biosynthesis Pathway Modulation

  2024cites this paper
• Inhibition of DUSP18 impairs cholesterol biosynthesis and promotes anti-tumor immunity in colorectal cancer

  2024cites this paper
• Phytochemical profiling of ethanolic extract of bee pollen using Gas Chromatography Mass Spectroscopy and its in silico analysis of hypocholeterolemic activity

  2024cites this paper
• The role of cholesterol metabolism in tumor therapy, from bench to bed

  2023cites this paper
• Liquiritigenin Enhances the Inhibitory Effects of the Cholesterol Biosynthesis Inhibitor RO 48-8071 on Cell Viability in Ovarian-Cancer Cells in Vitro

  2023influential citation
• Lanosterol synthase loss of function decreases the malignant phenotypes of HepG2 cells by deactivating the Src/MAPK signaling pathway

  2023cites this paper
• Cholesterol Biosynthesis Inhibitor RO 48–8071 Suppresses Growth of Epithelial Ovarian Cancer Cells in Vitro and In Vivo

  2023cites this paper
• Should oxidosqualene cyclase in the cholesterol biosynthetic pathway be considered an anti-cancer target?

  2022cites this paper
• De novo cholesterol biosynthesis: an additional therapeutic target for the treatment of postmenopausal breast cancer with excessive adipose tissue

  2022cites this paper
• The estrogen receptor beta agonist liquiritigenin enhances the inhibitory effects of the cholesterol biosynthesis inhibitor RO 48-8071 on hormone-dependent breast-cancer growth

  2022cites this paper
• Cholesterol biosynthesis inhibitor RO 48-8071 inhibits pancreatic ductal adenocarcinoma cell viability by deactivating the JNK and ERK/MAPK signaling pathway

  2021influential citation
• Modulation of lanosterol synthase drives 24,25-epoxysterol synthesis and oligodendrocyte formation.

  2021cites this paper
• Multiple unbiased approaches identify oxidosqualene cyclase as the molecular target of a promising anti-leishmanial

  2021cites this paper
• Unearthing the Janus-face cholesterogenesis pathways in cancer.

  2021cites this paper
• Cholesterol Metabolic Reprogramming in Cancer and Its Pharmacological Modulation as Therapeutic Strategy

  2021cites this paper
• Role of de novo cholesterol synthesis enzymes in cancer

  2020cites this paper
• Signaling pathways essential for triple‐negative breast cancer stem‐like cells

  2020cites this paper
• Cancer stem cells and breast cancer

  2020cites this paper
• Genkwadaphnin inhibits growth and invasion in hepatocellular carcinoma by blocking DHCR24-mediated cholesterol biosynthesis and lipid rafts formation

  2020cites this paper
• Harnessing Drug Repurposing for Exploration of New Diseases: An Insight to Strategies and Case Studies.

  2020cites this paper
• Multiple catalytic activities of human 17β-hydroxysteroid dehydrogenase type 7 respond differently to inhibitors.

  2019cites this paper
• https://researchopenworld.com/invited-commentary-proposing-potential-new-treatment-strategies-to-combat-breast-cancer-based-on-our-recently-published-manuscripts/#

  2018cites this paper
• Cholesterol biosynthesis inhibitor RO 48-8071 reduces progesterone receptor expression and inhibits progestin-dependent stem cell-like cell growth in hormone-dependent human breast cancer cells

  2017influential citation
• cholesterol biosynthesis inhibitor rO 48-8071 suppresses growth of hormone-dependent and castration-resistant prostate cancer cells

  2016influential citation
• Cholesterol biosynthesis inhibitor RO 48-8071 suppresses growth of hormone-dependent and castration-resistant prostate cancer cells

  2016cites this paper
• Arylpiperidines as a new class of oxidosqualene cyclase inhibitors.

  2016cites this paper
• The cholesterol biosynthesis enzyme oxidosqualene cyclase is a new target to impair tumour angiogenesis and metastasis dissemination

  2015cites this paper
• Inhibition of Cycloartenol Synthase (CAS) Function in Tobacco BY-2 Cell Suspensions: A Proteomic Analysis

  2015cites this paper
• Analysis and Experimental Inhibition of Distal Cholesterol Biosynthesis

  2015cites this paper
• Office of the Associate Dean for Research and Postgraduate Studies

  2014cites this paper
• QSAR model based on SMILES of inhibitory rate of 2, 3-diarylpropenoic acids on AKR1C3

  2014cites this paper